Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral tebipenem pivoxil hydrobromide versus intravenous ertapenem for complicated urinary tract infection or acute pyelonephritis
2018-003671-35Phase 3Completed
- Sponsor
- Spero Therapeutics
- Start
- Mar 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in complicated urinary tract infection (cUTI) and acute pyelonephritis comparing Oral tebipenem pivoxil hydrobromide arm with Intravenous ertapenem arm (2 arms). Primary endpoint: Overall response at test of cure in the microITT population. Started Mar 2019; status: completed.
02
Drugs
tebipenemertapenem
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on 2018-003671-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003671-35.